Urinary Didehydrodeoxycytidine Biomarker for Noninvasive SLE Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing systemic lupus erythematosus (SLE) and lupus nephritis are invasive and inaccurate, often requiring renal biopsy, which is risky and unsuitable for certain patients, and there is a lack of a reliable biomarker for early detection and prognosis prediction.
Innovation Solution
The use of 3′,4′-didehydro-3′-deoxycytidine in urine as a biomarker to detect systemic lupus erythematosus and lupus nephritis by measuring its concentration and comparing it to a reference value, allowing for non-invasive detection and prognosis prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If renal biopsy is performed for definitive diagnosis of lupus nephritis, then diagnostic accuracy is improved, but patient safety and ease of operation deteriorate due to invasive nature and bleeding risk
Solution Approach 1:
The patent introduces urinary 3′,4′-didehydro-3′-deoxycytidine as an intermediary biomarker that mediates between the need for accurate diagnosis and the desire to avoid invasive procedures. This metabolite serves as a surrogate indicator of lupus nephritis presence and prognosis without requiring direct tissue sampling, thereby resolving the contradiction between diagnostic accuracy and patient safety
Solution Approach 2:
The patent replaces the mechanical invasive procedure of renal biopsy with a non-invasive chemical measurement approach. Instead of physically extracting tissue samples through biopsy, the diagnosis is achieved by measuring the concentration of a specific urinary metabolite, substituting mechanical invasion with chemical analysis
2Measurement precision
If renal biopsy is performed for definitive diagnosis, then diagnostic accuracy is improved, but device complexity and ease of operation worsen due to procedural complexity
Solution Approach 1:
The complex mechanical procedure of renal biopsy is replaced with a simple chemical measurement of urinary metabolites. The diagnostic process transitions from a multi-step invasive procedure requiring specialized equipment and expertise to a straightforward biochemical analysis of urine samples
Solution Approach 2:
The patent extracts the essential diagnostic information from the complex biopsy procedure by identifying a specific urinary metabolite (3′,4′-didehydro-3′-deoxycytidine) that contains the necessary diagnostic data. This extraction simplifies the diagnostic process by focusing on a single measurable parameter rather than requiring comprehensive tissue analysis
3Adaptability or versatility
If multiple diagnostic criteria including antinuclear antibodies are used for SLE diagnosis, then diagnostic coverage is improved, but measurement precision deteriorates due to lack of single conclusive indicator
Solution Approach 1:
The patent changes the diagnostic parameter from multiple ambiguous indicators (symptoms and antinuclear antibodies) to a single precise measurement of urinary 3′,4′-didehydro-3′-deoxycytidine concentration. This parameter change transforms the diagnostic approach from multi-factorial uncertainty to single-factor precision while maintaining broad diagnostic coverage
Data Source
AI summary
An object of the present invention is to provide a method capable of detecting whether a subject has systemic lupus erythematosus (preferably nephrotic syndrome) with high accuracy without performing a renal biopsy, a biomarker for carrying out such detection, and the like. The concentration of 3′,4′-didehydro-3′-deoxycytidine in urine collected from a test subject is measured, and this concentration is compared with a reference concentration for control, which allows to detect whether the above-mentioned test subject has systemic lupus erythematosus (preferably lupus nephritis) with high accuracy.